-+ 0.00%
-+ 0.00%
-+ 0.00%

Compass Pathways publishes 2025 annual report

PUBT·04/16/2026 09:13:42
Listen to the news
Compass Pathways publishes 2025 annual report
  • Compass Pathways 2025 annual report highlighted progress toward first commercial launch of COMP360 psilocybin treatment for treatment-resistant depression, with NDA submission targeted for Q4 2026.
  • Phase 3 TRD program advanced, with COMP005 meeting primary endpoint in June 2025; COMP006 primary endpoint success announced in February 2026.
  • FDA accepted meeting request to discuss rolling submission and review following Phase 3 readouts.
  • PTSD development moved into late-stage planning, with FDA acceptance of IND in January 2026 enabling start of Phase 2b/3 COMP202 trial.
  • Commercial readiness work expanded through collaboration agreements with multiple US healthcare delivery systems, aiming to be launch-ready by end of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief on April 16, 2026, and is solely responsible for the information contained therein.